Annual report
2503.TEDINET S100VH7L
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.34T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.99T | 2022-01-01 → 2022-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.82T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.85T | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥125.3bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥150.3bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥139.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥191.4bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥99.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥124.5bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥58.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥111.0bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥59.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥71.9bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥85.8bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥150.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.35T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.54T | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.47T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.46T | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.82T | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.44T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.53T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.18T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥980.0bn | at 2022-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥894.2bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥838.6bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥118.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.5bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥161.7bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥242.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥135.6bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥219.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥164.8bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥329.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥10.4bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥56.4bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥116.0bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥58.1bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥167.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥180.5bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥52.5bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥71.87 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥135.08 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥71.73 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥85.57 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥71.86 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥135.07 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥71.7 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥85.54 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,458.68 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,398.47 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,210.16 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,072.69 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,005.96 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 35.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 38.5% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.2% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 34.1% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 5.0% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.7% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.8% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.9% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.2% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 31,934 | at 2024-12-31 | Cons. | Number of employees |
| Revenue | ¥194.6bn | 2024-01-01 → 2024-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥139.0bn | 2023-01-01 → 2023-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥152.8bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥139.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥138.8bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥114.5bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥64.4bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥60.4bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥62.2bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥76.9bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥73.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥72.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥332.2bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥77.2bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | −¥344.9bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥70.4bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥48.7bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥77.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥79.3bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.85T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.28T | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥1.90T | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.00T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.97T | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.29T | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.32T | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥561.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥964.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥951.1bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.01T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥987.1bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥12.2bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥20.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-425.84 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.91 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.24 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.67 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.37 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥71 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥71 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥69 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥693.7 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,190.61 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,174.47 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,208.06 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,184.06 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 30.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.1% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.1% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -45.2% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 914,000,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,067 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 977 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 914 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 1,156 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 1,117 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-01-01 → 2024-12-31 | ¥7.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-12-31 | 2113 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥97.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥21.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥76.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-12-31 | ¥362.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | ¥30m |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥10.4bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥86.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥86.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | −¥478.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥58.0bn |
| Alcoholic Beveragesreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥39.0bn |
| Alcoholic Beveragesreportable segment | employees | at 2024-12-31 | 8925 pure |
| Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥2.3bn |
| Alcoholic Beveragesreportable segment | segment assets | at 2024-12-31 | ¥1.37T |
| Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥124.0bn |
| Health Sciencereportable segment | capex | 2024-01-01 → 2024-12-31 | ¥6.7bn |
| Health Sciencereportable segment | employees | at 2024-12-31 | 5954 pure |
| Health Sciencereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥179.5bn |
| Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥175.3bn |
| Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥4.2bn |
| Health Sciencereportable segment | segment assets | at 2024-12-31 | ¥764.1bn |
| Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥10.9bn |
| Non Alcoholic Beveragesreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥20.9bn |
| Non Alcoholic Beveragesreportable segment | employees | at 2024-12-31 | 7887 pure |
| Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥567.8bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥564.9bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.0bn |
| Non Alcoholic Beveragesreportable segment | segment assets | at 2024-12-31 | ¥326.4bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥64.0bn |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥109.5bn |
| Pharmaceuticalsreportable segment | employees | at 2024-12-31 | 5669 pure |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥495.6bn |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥495.3bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥264m |
| Pharmaceuticalsreportable segment | segment assets | at 2024-12-31 | ¥1.01T |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥91.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-01-01 → 2023-12-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-12-31 | ¥94.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-12-31 | ¥27.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥66.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-12-31 | ¥510.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-12-31 | −¥60m |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥10.3bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥76.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥76.4bn |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | −¥719.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥54.2bn |
| Alcoholic Beveragesreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥39.1bn |
| Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥1.05T |
| Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥1.05T |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥2.3bn |
| Alcoholic Beveragesreportable segment | segment assets | at 2023-12-31 | ¥1.35T |
| Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥119.9bn |
| Health Sciencereportable segment | capex | 2023-01-01 → 2023-12-31 | ¥10.1bn |
| Health Sciencereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥108.0bn |
| Health Sciencereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥103.4bn |
| Health Sciencereportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥4.7bn |
| Health Sciencereportable segment | segment assets | at 2023-12-31 | ¥473.7bn |
| Health Sciencereportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥12.5bn |
| Non Alcoholic Beveragesreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥24.2bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥518.9bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥516.2bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥2.8bn |
| Non Alcoholic Beveragesreportable segment | segment assets | at 2023-12-31 | ¥287.4bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥52.4bn |
| Pharmaceuticalsreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥33.3bn |
| Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥442.2bn |
| Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥441.9bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥351m |
| Pharmaceuticalsreportable segment | segment assets | at 2023-12-31 | ¥971.4bn |
| Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥96.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,393
| Item | Context | Value | Unit |
|---|---|---|---|
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row23Member | 0.667 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row23Member | 0.379 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row23Member | 0.852 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row23Member | 0.769 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row24Member | 0.400 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row24Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row24Member | 0.456 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row24Member | 0.718 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row24Member | 0.846 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row25Member | 0.017 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row25Member | 0.333 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row25Member | 0.753 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row25Member | 0.745 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row25Member | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row26Member | 0.102 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row26Member | 0.333 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row26Member | 0.840 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row26Member | 0.804 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row26Member | 1.704 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 71 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 15.9 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 42.9 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 0.97 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 72 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row6Member | 72 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row7Member | 2.50 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row8Member | 63.6 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row9Member | 18.0 | |
| Research and development expenses research and development activities | CurrentYearDuration | 116100000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember | 800000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 800000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember | 102800000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember | 2700000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 103123000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00395-000AlcoholicBeveragesReportableSegmentMember | 37251000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 19722000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00395-000PharmaceuticalsReportableSegmentMember | 30199000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00395-000HealthScienceReportableSegmentMember | 5528000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 914000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 914000000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 914000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 914000000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 3 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 175 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 47 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 2135 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 747 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 648 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 425873 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |